Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cell Microbiol. 2013 Jan 20;15(7):1127–1142. doi: 10.1111/cmi.12103

Figure 5. Exogenous galectin-3 augments phagocytosis of C. parapsilosis and C. albicans.

Figure 5

Results are mean ± SEM of at least three different neutrophil donors. * p ≤ 0.05, **p≤ 0.005, ***p≤ 0.0005 compared to untreated controls. (A) Phagocytosis rates of C. albicans and C. parapsilosis at an E:T ratio of 1:20 and 1:5, respectively, after neutrophil treatment with rGal3 at the indicated doses. Untreated neutrophils (0 μg) were used as a control. Phagocytosis of C. parapsilosis at an E:T ratio of 1:5 (B) and C. albicans at an E:T ratio of 1:20 (C) after treatment with 2 μg of rGal3 alone or after pretreatment with 25 μg of gal3 blocking antibody before adding neutrophils (AB + rGal3). Untreated neutrophils (CT) were used as control. Phagocytosis of C. parapsilosis yeast at an E:T ratio of 1:5 (D) and C. albicans yeast at an E:T ratio of 1:20 (E) was measured after treatment with 3 μg full length recombinant gal3 (FL-G3) or a truncated form of recombinant gal3 containing only the CRD domain (CRD-G3). FL-G3 and CRD-G3 were pretreated with either β-lactose (β-lac) to inhibit CRD binding or a gal3 antibody (AB) that inhibits regulatory domain oligomerization prior to neutrophil treatment.